score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable		Clinical evidence		Somatic Variant	AR	Missense	p.L702H	0.9545	44.0	0.0	0.0								Putatively Actionable	Abiraterone	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220						0	4.0	0.0	0.7701	AR p.L702H (Missense)		PROS01448-6115250	PROS01448-6115250-Tumor-SM-67ES4	PROS01448-6115250-Normal-SM-67ET3
Investigate Actionability - High	Inferential			Mutational Signature	COSMIC Signature 3		0.23						Investigate Actionability - High	Platinum	Chemotherapy	Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.	Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.	https://doi.org/10.1038/ncomms9683												0				COSMIC Signature 3 (23%)		PROS01448-6115250		
Investigate Actionability - Low	Clinical trial	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.H2361fs	0.4094	171.0	0.0	0.0		Investigate Actionability - Low	Olaparib	Targeted therapy	Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.	Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373(18):1697-708.	https://doi.org/10.1056/NEJMoa1506859	Investigate Actionability - Low	Olaparib	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	0.0	0.0	0.0	BRCA2 p.H2361fs (Frameshift)	0.0	PROS01448-6115250	PROS01448-6115250-Tumor-SM-67ES4	PROS01448-6115250-Normal-SM-67ET3
Investigate Actionability - Low			Preclinical	Copy Number	TPX2	Deletion				0.0	0.0														Investigate Actionability - Low	0.0	Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth	"Sillars-Hardebol, Anke H., et al. ""TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression."" Gut 61.11 (2012): 1568-1575."	https://doi.org/10.1136/gutjnl-2011-301153	0				TPX2 Deletion		PROS01448-6115250	PROS01448-6115250-Tumor-SM-67ES4	
Biologically Relevant				Copy Number	ZRSR2	Deletion				0.0	0.0																			0				ZRSR2 Deletion		PROS01448-6115250	PROS01448-6115250-Tumor-SM-67ES4	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																							0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		PROS01448-6115250		
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.227																							0				COSMIC Signature 1 (23%)		PROS01448-6115250		
